Top

Published in:

01-10-2020 | Coronavirus | Review

Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment

Authors: Sanket Shah, Debashish Danda, Chengappa Kavadichanda, Saibal Das, M. B. Adarsh, Vir Singh Negi

Published in: Rheumatology International | Issue 10/2020

Abstract

The coronavirus disease-2019 (COVID-19) pandemic is likely to pose new challenges to the rheumatology community in the near and distant future. Some of the challenges, like the severity of COVID-19 among patients on immunosuppressive agents, are predictable and are being evaluated with great care and effort across the globe. A few others, such as atypical manifestations of COVID-19 mimicking rheumatic musculoskeletal diseases (RMDs) are being reported. Like in many other viral infections, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can potentially lead to an array of rheumatological and autoimmune manifestations by molecular mimicry (cross-reacting epitope between the virus and the host), bystander killing (virus-specific CD8 + T cells migrating to the target tissues and exerting cytotoxicity), epitope spreading, viral persistence (polyclonal activation due to the constant presence of viral antigens driving immune-mediated injury) and formation of neutrophil extracellular traps. In addition, the myriad of antiviral drugs presently being tried in the treatment of COVID-19 can result in several rheumatic musculoskeletal adverse effects. In this review, we have addressed the possible spectrum and mechanisms of various autoimmune and rheumatic musculoskeletal manifestations that can be precipitated by COVID-19 infection, its therapy, and the preventive strategies to contain the infection.

WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/?gclid=Cj0KCQjwwr32BRD4ARIsAAJNf_0jdmZQ1hkz7onImyjahwc-N0H4WTwXnVU7bgQObfk_Vct9yucybbkaAk0oEALw_wcB. Accessed 28 May 2020

El-Aziz TMA, Stockand JD (2020) Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol. https://doi.org/10.1016/j.meegid.2020.104327CrossRef

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. https://doi.org/10.1038/s41577-020-0311-8CrossRefPubMedPubMedCentral

Verdoni L, Mazza A, Gervasoni A et al (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet Lond Engl. https://doi.org/10.1016/S0140-6736(20)31103-XCrossRef

Toscano G, Palmerini F, Ravaglia S et al (2020) Guillain-Barré Syndrome associated with SARS-CoV-2. N Engl J Med. https://doi.org/10.1056/NEJMc2009191CrossRefPubMedPubMedCentral

Alberti P, Beretta S, Piatti M et al (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflammation 7(4):e741. https://doi.org/10.1212/NXI.0000000000000741CrossRef

The Lancet Rheumatology (2020) Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30082-5CrossRefPubMedPubMedCentral

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05073-9CrossRefPubMedPubMedCentral

Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primer 6(1):1–21. https://doi.org/10.1038/s41572-020-0160-6CrossRef

10.

Kostine M, Cappelli LC, Calabrese C et al (2019) Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis 78(6):860–862. https://doi.org/10.1136/annrheumdis-2018-214748CrossRefPubMed

11.

Batlle D, Wysocki J (1979) Satchell K (2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci Lond Engl 134(5):543–545. https://doi.org/10.1042/CS20200163CrossRef

12.

Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631–637. https://doi.org/10.1002/path.1570CrossRefPubMedPubMedCentral

13.

Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323(13):1239–1242. https://doi.org/10.1001/jama.2020.2648CrossRefPubMed

14.

Giacomelli A, Pezzati L, Conti F et al (2020) Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa330CrossRefPubMed

15.

Lechien JR, Chiesa-Estomba CM, Hans S, Barillari MR, Jouffe L, Saussez S (2020) Loss of smell and taste in 2013 European patients with mild to moderate COVID-19. Ann Intern Med. https://doi.org/10.7326/M20-2428CrossRefPubMedPubMedCentral

16.

Jin X, Lian J-S, Hu J-H et al (2020) Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 69(6):1002–1009. https://doi.org/10.1136/gutjnl-2020-320926CrossRefPubMed

17.

Goyal P, Choi JJ, Pinheiro LC et al (2020) Clinical characteristics of Covid-19 in New York City. N Engl J Med 382(24):2372–2374. https://doi.org/10.1056/NEJMc2010419CrossRefPubMed

18.

Wu P, Duan F, Luo C et al (2020) Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province. China JAMA Ophthalmol 138(5):575–578. https://doi.org/10.1001/jamaophthalmol.2020.1291CrossRefPubMed

19.

CDC Coronavirus Disease 2019 (COVID-19) Centers for Disease Control and Prevention (2020). https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

20.

Gianfrancesco MA, Hyrich KL, Gossec L et al (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2(5):e250–e253. https://doi.org/10.1016/S2665-9913(20)30095-3CrossRefPubMedPubMedCentral

21.

Overview of Public Health and Social Measures in the context of COVID-19. https://www.who.int/publications-detail-redirect/overview-of-public-health-and-social-measures-in-the-context-of-covid-19

22.

Beydon M, Chevalier K, Tabaa OA et al (2020) Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217573CrossRefPubMed

23.

Casas CG, Català A, Hernández GC, et al (2020) Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 10.1111/bjd.19163

24.

Oxley TJ, Mocco J, Majidi S et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382(20):e60. https://doi.org/10.1056/NEJMc2009787CrossRefPubMed

25.

Inciardi RM, Lupi L, Zaccone G et al (2020) Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1096CrossRefPubMedPubMedCentral

26.

Kim I-C, Kim JY, Kim HA, Han S (2020) COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J 41(19):1859–1859. https://doi.org/10.1093/eurheartj/ehaa288CrossRefPubMed

27.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

28.

Gazzaruso C, Carlo Stella N, Mariani G et al (2020) High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05180-7CrossRefPubMedPubMedCentral

29.

Harzallah I, Debliquis A, Drénou B (2020) Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost. https://doi.org/10.1111/jth.14867CrossRefPubMedPubMedCentral

30.

Zhang Y, Xiao M, Zhang S et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38. https://doi.org/10.1056/NEJMc2007575CrossRefPubMed

31.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRef

32.

Esposito S, Noviello S, Pagliano P (2020) Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med 28(2):198–211PubMed

33.

Casado E, Gratacós J, Tolosa C et al (2006) Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 65(3):385–390. https://doi.org/10.1136/ard.2004.023200CrossRefPubMed

34.

Hayden FG, Shindo N (2019) Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 32(2):176–186. https://doi.org/10.1097/QCO.0000000000000532CrossRefPubMedPubMedCentral

35.

Chandwani A, Shuter J (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4(5):1023–1033PubMedPubMedCentral

36.

Naik GS, Tyagi MG (2012) A pharmacological profile of ribavirin and monitoring of its plasma concentration in Chronic Hepatitis C Infection. J Clin Exp Hepatol 2(1):42–54. https://doi.org/10.1016/S0973-6883(12)60090-5CrossRefPubMedPubMedCentral

37.

Psarras A, Emery P, Vital EM (2017) Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology 56(10):1662–1675. https://doi.org/10.1093/rheumatology/kew431CrossRefPubMed

38.

Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847. https://doi.org/10.1111/jth.14768CrossRefPubMedPubMedCentral

39.

Wichmann D, Sperhake J-P, Lütgehetmann M et al (2020) Autopsy findings and venous thromboembolism in patients With COVID-19. Ann Intern Med. https://doi.org/10.7326/M20-2003CrossRefPubMedPubMedCentral

40.

Levi M, Thachil J, Iba T, Levy JH (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. https://doi.org/10.1016/S2352-3026(20)30145-9CrossRefPubMedPubMedCentral

41.

Thachil J, Srivastava A (2020) SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost. https://doi.org/10.1055/s-0040-1712155CrossRefPubMedPubMedCentral

42.

Stockschlaeder M, Schneppenheim R, Budde U (2014) Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis Int J Haemost Thromb 25(3):206–216. https://doi.org/10.1097/MBC.0000000000000065CrossRef

43.

Zuo Y, Zuo M, Yalavarthi S et al (2020) Neutrophil extracellular traps and thrombosis in COVID-19. MedRxiv. https://doi.org/10.1101/2020.04.30.20086736CrossRefPubMedPubMedCentral

44.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099. https://doi.org/10.1111/jth.14817CrossRefPubMed

45.

Shoenfeld Y, Isenberg DA (1989) The mosaic of autoimmunity. Immunol Today 10(4):123–126. https://doi.org/10.1016/0167-5699(89)90245-4CrossRefPubMed

46.

Arleevskaya MI, Manukyan G, Inoue R, Aminov R (2017) Editorial: microbial and environmental factors in autoimmune and inflammatory diseases. Front Immunol. https://doi.org/10.3389/fimmu.2017.00243CrossRefPubMedPubMedCentral

47.

Toplak N, Avčin T (2009) Influenza and autoimmunity. Ann N Y Acad Sci 1173(1):619–626. https://doi.org/10.1111/j.1749-6632.2009.04759.xCrossRefPubMed

48.

Acosta-Ampudia Y, Monsalve DM, Castillo-Medina LF et al (2018) Autoimmune neurological conditions associated with zika virus infection. Front Mol Neurosci. https://doi.org/10.3389/fnmol.2018.00116CrossRefPubMedPubMedCentral

49.

Tanay A (2017) Chikungunya virus and autoimmunity. Curr Opin Rheumatol 29(4):389–393. https://doi.org/10.1097/BOR.0000000000000396CrossRefPubMed

50.

Fausther-Bovendo H, Qiu X, McCorrister S et al (2017) Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep 7:42147. https://doi.org/10.1038/srep42147CrossRefPubMedPubMedCentral

51.

Fujinami RS, von Herrath MG, Christen U, Whitton JL (2006) Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19(1):80–94. https://doi.org/10.1128/CMR.19.1.80-94.2006CrossRefPubMedPubMedCentral

52.

Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM (2019) Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses 11(8):762. https://doi.org/10.3390/v11080762CrossRefPubMedCentral

53.

Kim B, Kaistha SD, Rouse BT (2006) Viruses and autoimmunity. Autoimmunity 39(1):71–77. https://doi.org/10.1080/08916930500484708CrossRefPubMed

54.

Cusick MF, Libbey JE, Fujinami RS (2012) Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 42(1):102–111. https://doi.org/10.1007/s12016-011-8294-7CrossRefPubMed

55.

Lyons-Weiler J (2020) Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun 3:100051. https://doi.org/10.1016/j.jtauto.2020.100051CrossRefPubMedPubMedCentral

56.

Megremis S, Walker TDJ, He X et al (2020) Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217522CrossRefPubMed

57.

Totura AL, Baric RS (2012) SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2(3):264–275. https://doi.org/10.1016/j.coviro.2012.04.004CrossRefPubMedPubMedCentral

58.

Nguyen A, David JK, Maden SK et al (2020) Human leukocyte antigen susceptibility map for SARS-CoV-2. J Virol. https://doi.org/10.1128/JVI.00510-20CrossRefPubMedPubMedCentral

59.

Charfi A, Mahfoudh N, Kamoun A et al (2020) Association of HLA Alleles with Primary Sjögren Syndrome in the South Tunisian Population. Med Princ Pract 29(1):32–38. https://doi.org/10.1159/000501896CrossRefPubMed

60.

Choukri F, Chakib A, Himmich H, Hüe S, Caillat-Zucman S (2001) HLA-B∗51 and B∗15 alleles confer predisposition to Behçet’s disease in Moroccan patients. Hum Immunol 62(2):180–185. https://doi.org/10.1016/S0198-8859(00)00249-4CrossRefPubMed

61.

Lehmann PV, Targoni OS, Forsthuber TG (1998) Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Immunol Rev 164(1):53–61. https://doi.org/10.1111/j.1600-065X.1998.tb01207.xCrossRefPubMed

62.

Sokolove J, Bromberg R, Deane KD et al (2012) Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE. https://doi.org/10.1371/journal.pone.0035296CrossRefPubMedPubMedCentral

63.

Deshmukh US, Gaskin F, Lewis JE, Kannapell CC, Fu SM (2003) Mechanisms of autoantibody diversification to SLE-related autoantigens. Ann N Y Acad Sci 987(1):91–98. https://doi.org/10.1111/j.1749-6632.2003.tb06036.xCrossRefPubMed

64.

Arbuckle MR, McClain MT, Rubertone MV et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533. https://doi.org/10.1056/NEJMoa021933CrossRefPubMed

65.

Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvennick N (1998) Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry. Nat Med 4(7):781–785. https://doi.org/10.1038/nm0798-781CrossRefPubMed

66.

McCoy L, Tsunoda I, Fujinami RS (2006) Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 39(1):9–19. https://doi.org/10.1080/08916930500484799CrossRefPubMed

67.

Ando K, Hiroishi K, Kaneko T et al (1997) Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 158(11):5283–5291PubMed

68.

Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80(5):695–705. https://doi.org/10.1016/0092-8674(95)90348-8CrossRefPubMedPubMedCentral

69.

Ramos-Casals M, Loustaud-Ratti V, De Vita S et al (2005) Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 84(2):81–89. https://doi.org/10.1097/01.md.0000157397.30055.c9CrossRef

70.

Ramos-Casals M, García-Carrasco M, Cervera R, Font J (1999) Sjögren’s syndrome and hepatitis C virus. Clin Rheumatol 18(2):93–100. https://doi.org/10.1007/s100670050064CrossRefPubMed

71.

Zheng M, Gao Y, Wang G et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17(5):533–535. https://doi.org/10.1038/s41423-020-0402-2CrossRefPubMedPubMedCentral

72.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRef

73.

Kim JY, Ko JH, Kim Y et al (2020) Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci 35(7):e86. https://doi.org/10.3346/jkms.2020.35.e86CrossRefPubMedPubMedCentral

74.

Ehrenfeld M, Tincani A, Andreoli L et al (2020) Covid-19 and autoimmunity. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2020.102597CrossRefPubMedPubMedCentral

75.

Podolska MJ, Biermann MH, Maueröder C, Hahn J, Herrmann M (2015) Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res 8:161–171. https://doi.org/10.2147/JIR.S70325CrossRefPubMedPubMedCentral

76.

Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M (1985) Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 56(2):651–654CrossRefPubMedPubMedCentral

77.

Nanbo A, Inoue K, Adachi-Takasawa K, Takada K (2002) Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt’s lymphoma. EMBO J 21(5):954–965. https://doi.org/10.1093/emboj/21.5.954CrossRefPubMedPubMedCentral

78.

de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14(8):523–534. https://doi.org/10.1038/nrmicro.2016.81CrossRefPubMedPubMedCentral

79.

Zuo Y, Yalavarthi S, Shi H et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight. https://doi.org/10.1172/jci.insight.138999CrossRefPubMedPubMedCentral

80.

Papayannopoulos V (2018) Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18(2):134–147. https://doi.org/10.1038/nri.2017.105CrossRefPubMed

81.

Wigerblad G, Kaplan MJ (2020) NETs spread ever wider in rheumatic diseases. Nat Rev Rheumatol 16(2):73–74. https://doi.org/10.1038/s41584-019-0352-1CrossRefPubMed

82.

Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China JAMA 323(11):1061–1069. https://doi.org/10.1001/jama.2020.1585CrossRefPubMed

83.

Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A (2010) Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 191(3):677–691. https://doi.org/10.1083/jcb.201006052CrossRefPubMedPubMedCentral

84.

Chan KH, Lee P, Chan CY, Lam KBH, Ho P (2020) Monitoring respiratory infections in covid-19 epidemics. BMJ. https://doi.org/10.1136/bmj.m1628CrossRefPubMedPubMedCentral

85.

Baker MG, Gurney J, Oliver J et al (2019) Risk factors for acute rheumatic fever: literature review and protocol for a case-control study in New Zealand. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16224515CrossRefPubMedPubMedCentral

86.

Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB (2015) The hygiene hypothesis: current perspectives and future therapies. Immunotargets Ther 4:143–157. https://doi.org/10.2147/ITT.S61528CrossRefPubMedPubMedCentral

87.

Bach J-F (2018) The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol 18(2):105–120. https://doi.org/10.1038/nri.2017.111CrossRefPubMed

88.

Manasson J, Blank RB, Scher JU (2020) The microbiome in rheumatology: where are we and where should we go? Ann Rheum Dis 79(6):727–733. https://doi.org/10.1136/annrheumdis-2019-216631CrossRefPubMed

89.

Stojanovich L, Marisavljevich D (2008) Stress as a trigger of autoimmune disease. Autoimmun Rev 7(3):209–213. https://doi.org/10.1016/j.autrev.2007.11.007CrossRefPubMed

90.

Le TT, Andreadakis Z, Kumar A et al (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19(5):305–306. https://doi.org/10.1038/d41573-020-00073-5CrossRef

91.

Ahmed SS, Volkmuth W, Duca J et al (2015) Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 7(294):294ra105. https://doi.org/10.1126/scitranslmed.aab2354CrossRefPubMed

92.

Agrawal AS, Tao X, Algaissi A et al (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccines Immunother 12(9):2351–2356. https://doi.org/10.1080/21645515.2016.1177688CrossRef

93.

Deming D, Sheahan T, Heise M et al (2006) Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3(12):e525. https://doi.org/10.1371/journal.pmed.0030525CrossRefPubMedPubMedCentral

94.

Li G, Fan Y, Lai Y et al (2020) Coronavirus infections and immune responses. J Med Virol 92(4):424–432. https://doi.org/10.1002/jmv.25685CrossRefPubMedPubMedCentral

95.

Siddiqi HK, Mehra MR (2020) COVID-19 Illness in Native and Immunosuppressed States: a clinical-therapeutic staging proposal. J Heart Lung Transpl. https://doi.org/10.1016/j.healun.2020.03.012CrossRef

96.

Sönmez HE, Demir S, Bilginer Y, Özen S (2018) Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 37(12):3329–3335. https://doi.org/10.1007/s10067-018-4095-1CrossRefPubMed

97.

Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ (2019) The other side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book 39:433–444. https://doi.org/10.1200/EDBK_238691CrossRefPubMed

98.

Huet T, Beaussier H, Voisin O et al (2020) Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30164-8CrossRefPubMedPubMedCentral

99.

McGonagle D, Sharif K, O’Regan A, Bridgewood C (2020) The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537CrossRefPubMedPubMedCentral

100.

Watanabe E, Sugawara H, Yamashita T, Ishii A, Oda A, Terai C (2016) Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still’s disease: a case-based review. Case Rep Med 2016:5656320. https://doi.org/10.1155/2016/5656320CrossRefPubMedPubMedCentral

101.

Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci 117(20):10970–10975. https://doi.org/10.1073/pnas.2005615117CrossRefPubMedPubMedCentral

102.

Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D (2020) Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. https://doi.org/10.1016/j.jinf.2020.04.017CrossRefPubMedPubMedCentral

Title: Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment
Authors: Sanket Shah
Debashish Danda
Chengappa Kavadichanda
Saibal Das
M. B. Adarsh
Vir Singh Negi
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Coronavirus
SARS-CoV-2
COVID-19
Published in: Rheumatology International / Issue 10/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04639-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

IgG4-related pleural disease with aortitis and submandibular glands involvement successfully treated with corticosteroid: case-based review

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19

A study of antigen-specific anti-cytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies

Red cell distribution width and neutrophil–lymphocyte ratio in rheumatoid arthritis

Trends in idiopathic inflammatory myopathies: cross-sectional data from the German National Database

Validity and reliability of the Patient Health Questionnaire-8 in Swedish for individuals with systemic sclerosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page